Furthermore, IGF2BP2 inhibitors, CWI1-1 and CWI1-2, have also been identified, with CWI1-2 (IC50 = 203.1-781.6 nM in leukemia cell lines) demonstrating stronger anti-tumor effects on acute myelocytic leukemia in vitro and in vivo [83]. Here, IGF2BP2 is linked to acute myeloid leukemia.